Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Catherine Humbrecht-Kraut

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03)

Clinical Cancer Research

Cancer Research

Oncology

2019

English

Related publications

Melphalan and Prednisone Versus Melphalan, Prednisone and Thalidomide for Elderly and/or Transplant Ineligible Patients With Multiple Myeloma: A Meta-Analysis

English

Lenalidomide−prednisone Induction Followed by Lenalidomide−melphalan−prednisone Consolidation and Lenalidomide−prednisone Maintenance in Newly Diagnosed Elderly Unfit Myeloma Patients

English

Phase I/Ii Study of Carfilzomib, Bendamustine, and Dexamethasone (CBD) in Patients With Newly Diagnosed Multiple Myeloma

English

First-Line Therapy With Either Bortezomib-Melphalan-Prednisone or Lenalidomide-Dexamethasone Followed by Lenalidomide for Transplant-Ineligible Multiple Myeloma Patients: A Pooled Analysis of Two Randomized Trials

Haematologica

Hematology

2019

English

Pcn340 - Real-World Usage of Bortezomib in Combination With Melphalan and Prednisone (Vmp) as Frontline (Fl) Treatment in Stem Cell Transplant (Sct) Ineligible Multiple Myeloma (Mm) Patients Across Eu5 Countries

English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology

Hematology

2019

English

High-Dose BCNU/Melphalan Conditioning Regimen Before Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Bone Marrow Transplantation

Transplantation

Hematology

2017

English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology

Hematology

2019

English

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Clinical Lymphoma, Myeloma and Leukemia

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Catherine Humbrecht-Kraut

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03)

Related publications

Melphalan and Prednisone Versus Melphalan, Prednisone and Thalidomide for Elderly and/or Transplant Ineligible Patients With Multiple Myeloma: A Meta-Analysis

Lenalidomide−prednisone Induction Followed by Lenalidomide−melphalan−prednisone Consolidation and Lenalidomide−prednisone Maintenance in Newly Diagnosed Elderly Unfit Myeloma Patients

Phase I/Ii Study of Carfilzomib, Bendamustine, and Dexamethasone (CBD) in Patients With Newly Diagnosed Multiple Myeloma

First-Line Therapy With Either Bortezomib-Melphalan-Prednisone or Lenalidomide-Dexamethasone Followed by Lenalidomide for Transplant-Ineligible Multiple Myeloma Patients: A Pooled Analysis of Two Randomized Trials

Pcn340 - Real-World Usage of Bortezomib in Combination With Melphalan and Prednisone (Vmp) as Frontline (Fl) Treatment in Stem Cell Transplant (Sct) Ineligible Multiple Myeloma (Mm) Patients Across Eu5 Countries

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

High-Dose BCNU/Melphalan Conditioning Regimen Before Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)